Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BAYRY Bayer Aktiengesellschaft	$11.11	$11.28	$6.90 ▼ $14.85	$43.66B	0.62	1.66 million shs	1.26 million shs
INVA Innoviva	$22.46	$22.89	$16.52 ▼ $25.15	$1.66B	0.38	684,891 shs	1.19 million shs
PFE Pfizer	$25.92 +0.1%	$26.86	$22.88 ▼ $28.75	$147.72B	0.35	37.77 million shs	22.30 million shs
SNY Sanofi	$44.29	$45.58	$42.33 ▼ $53.03	$108.02B	0.35	2.68 million shs	2.76 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BAYRY Bayer Aktiengesellschaft	0.00%	+1.93%	-0.80%	-11.40%	+58.71%
INVA Innoviva	0.00%	+2.23%	-4.71%	-4.06%	+18.40%
PFE Pfizer	0.00%	+2.41%	-4.03%	-4.13%	+11.08%
SNY Sanofi	0.00%	+3.75%	-5.32%	-6.20%	-14.79%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BAYRY Bayer Aktiengesellschaft	$11.11	$11.28	$6.90 ▼ $14.85	$43.66B	0.62	1.66 million shs	1.26 million shs
INVA Innoviva	$22.46	$22.89	$16.52 ▼ $25.15	$1.66B	0.38	684,891 shs	1.19 million shs
PFE Pfizer	$25.92 +0.1%	$26.86	$22.88 ▼ $28.75	$147.72B	0.35	37.77 million shs	22.30 million shs
SNY Sanofi	$44.29	$45.58	$42.33 ▼ $53.03	$108.02B	0.35	2.68 million shs	2.76 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BAYRY Bayer Aktiengesellschaft	0.00%	+1.93%	-0.80%	-11.40%	+58.71%
INVA Innoviva	0.00%	+2.23%	-4.71%	-4.06%	+18.40%
PFE Pfizer	0.00%	+2.41%	-4.03%	-4.13%	+11.08%
SNY Sanofi	0.00%	+3.75%	-5.32%	-6.20%	-14.79%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BAYRY Bayer Aktiengesellschaft	3.22	Buy	N/A	N/A
INVA Innoviva	2.57	Moderate Buy	$36.20	61.18% Upside
PFE Pfizer	2.19	Hold	$28.61	10.39% Upside
SNY Sanofi	2.47	Hold	$51.00	15.15% Upside

Current Analyst Ratings Breakdown

Latest BAYRY, PFE, SNY, and INVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2026	BAYRY Bayer Aktiengesellschaft	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/14/2026	PFE Pfizer	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underperform	$26.00
5/13/2026	SNY Sanofi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
5/8/2026	BAYRY Bayer Aktiengesellschaft	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
5/7/2026	INVA Innoviva	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$35.00 ➝ $42.00
5/6/2026	PFE Pfizer	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
5/1/2026	SNY Sanofi	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$52.00
5/1/2026	SNY Sanofi	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight
4/29/2026	SNY Sanofi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
4/29/2026	PFE Pfizer	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$26.00 ➝ $27.00
4/27/2026	SNY Sanofi	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BAYRY Bayer Aktiengesellschaft	$51.55B	0.85	$2.18 per share	5.09	$7.50 per share	1.48
INVA Innoviva	$411.33M	4.03	$5.04 per share	4.46	$18.18 per share	1.24
PFE Pfizer	$62.58B	2.36	$4.40 per share	5.89	$15.86 per share	1.63
SNY Sanofi	$49.35B	2.19	$7.06 per share	6.27	$35.10 per share	1.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BAYRY Bayer Aktiengesellschaft	-$4.10B	-$0.64	N/A	8.29	3.54	-4.75%	17.74%	4.88%	8/4/2026 (Estimated)
INVA Innoviva	$271.17M	$6.01	3.74	8.98	N/A	119.89%	33.33%	22.67%	8/5/2026 (Estimated)
PFE Pfizer	$7.77B	$1.31	19.79	9.06	N/A	11.83%	19.44%	8.41%	8/4/2026 (Estimated)
SNY Sanofi	$8.84B	$3.58	12.37	8.50	1.09	16.95%	13.39%	7.58%	7/30/2026 (Estimated)

Latest BAYRY, PFE, SNY, and INVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2026	Q1 2026	BAYRY Bayer Aktiengesellschaft	$0.64	$0.79	+$0.15	$0.82	$15.77 billion	$15.73 billion
5/6/2026	Q1 2026	INVA Innoviva	$0.43	$0.44	+$0.01	$2.22	$101.57 million	$97.99 million
5/5/2026	Q1 2026	PFE Pfizer	$0.7220	$0.75	+$0.0280	$0.47	$13.84 billion	$14.45 billion
3/4/2026	Q4 2025	BAYRY Bayer Aktiengesellschaft	$0.18	$0.1794	-$0.0006	$1.47	$13.08 billion	$13.24 billion
2/25/2026	Q4 2025	INVA Innoviva	$0.34	$1.94	+$1.60	$1.94	$102.62 million	$114.61 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BAYRY Bayer Aktiengesellschaft	$0.02	0.18%	N/A	N/A	N/A
INVA Innoviva	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.64%	-13.20%	131.30%	16 Years
SNY Sanofi	$1.76	3.97%	+6.46%	49.16%	N/A

Latest BAYRY, PFE, SNY, and INVA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/22/2026	PFE Pfizer	quarterly	$0.43	6.71%	5/8/2026	5/8/2026	6/12/2026
4/14/2026	SNY Sanofi	annual	$2.4225	5.59%	5/4/2026	5/4/2026	6/3/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BAYRY Bayer Aktiengesellschaft	1.22	1.01	0.63
INVA Innoviva	0.19	21.13	20.07
PFE Pfizer	0.67	1.25	0.94
SNY Sanofi	0.17	1.01	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BAYRY Bayer Aktiengesellschaft	N/A
INVA Innoviva	99.12%
PFE Pfizer	68.36%
SNY Sanofi	14.03%

Insider Ownership

Company	Insider Ownership
BAYRY Bayer Aktiengesellschaft	N/A
INVA Innoviva	2.01%
PFE Pfizer	0.62%
SNY Sanofi	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BAYRY Bayer Aktiengesellschaft	88,078	3.93 billion	N/A	Not Optionable
INVA Innoviva	100	73.81 million	72.33 million	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable
SNY Sanofi	74,846	2.44 billion	2.41 billion	Optionable

BAYRY, PFE, SNY, and INVA Headlines

Recent News About These Companies

Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails

May 22 at 1:15 PM | zacks.com

sanofi - SNY

May 21, 2026 | foxbusiness.com

Sanofi (NASDAQ:SNY) Given Consensus Recommendation of "Hold" by Brokerages

May 20, 2026 | americanbankingnews.com

Sanofi: Information concerning the total number of voting rights and shares - April 2026

May 19, 2026 | globenewswire.com

Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?

May 19, 2026 | zacks.com

Sanofi says rare lung disease drug outperforms standard care in trial

May 18, 2026 | reuters.com

Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

May 18, 2026 | globenewswire.com

3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally

May 13, 2026 | fool.com

Erste Group Bank Decreases Earnings Estimates for Sanofi

May 11, 2026 | marketbeat.com

DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects

May 8, 2026 | zacks.com

Truist Financial Corp Sells 37,780 Shares of Sanofi $SNY

May 7, 2026 | marketbeat.com

Sanofi asks to pull diabetes drug out of FDA voucher program, STAT News reports

May 6, 2026 | reuters.com

Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1

May 6, 2026 | prnewswire.com

Sanofi $SNY Shares Sold by UBS Group AG

May 6, 2026 | marketbeat.com

Sanofi (NASDAQ:SNY) Sets New 1-Year Low - Should You Sell?

May 5, 2026 | marketbeat.com

Sanofi (NASDAQ:SNY) Shares Gap Down Following Analyst Downgrade

May 4, 2026 | marketbeat.com

M&T Bank Corp Sells 402,012 Shares of Sanofi $SNY

May 3, 2026 | marketbeat.com

Morgan Stanley Downgrades Sanofi (NASDAQ:SNY) to Equal Weight

May 1, 2026 | marketbeat.com

Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi

April 29, 2026 | globenewswire.com

Sanofi (NASDAQ:SNY) Upgraded at Argus

April 29, 2026 | marketbeat.com

Erste Group Bank Issues Positive Outlook for Sanofi Earnings

April 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BAYRY, PFE, SNY, and INVA Company Descriptions

Bayer Aktiengesellschaft OTCMKTS:BAYRY

$11.11 0.00 (0.00%)

As of 05/22/2026 04:00 PM Eastern

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Innoviva NASDAQ:INVA

$22.46 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$22.25 -0.21 (-0.93%)

As of 05/22/2026 06:53 PM Eastern

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Pfizer NYSE:PFE

$25.92 +0.02 (+0.07%)

Closing price 05/22/2026 03:59 PM Eastern

Extended Trading

$25.91 -0.01 (-0.03%)

As of 05/22/2026 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sanofi NASDAQ:SNY

$44.29 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$44.44 +0.15 (+0.34%)

As of 05/22/2026 06:49 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BAYRY, PFE, SNY, and INVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BAYRY, PFE, SNY, and INVA Earnings

Compare Dividends

Latest BAYRY, PFE, SNY, and INVA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BAYRY, PFE, SNY, and INVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BAYRY, PFE, SNY, and INVA Company Descriptions

Bayer Aktiengesellschaft OTCMKTS:BAYRY

Innoviva NASDAQ:INVA

Pfizer NYSE:PFE

Sanofi NASDAQ:SNY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools